
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics Inc. is positioned favorably due to its bifunctional therapy ficerafusp alfa, which has demonstrated superior overall response rates (ORR) compared to established treatments such as Keytruda in a comparable patient population. The combination of ficerafusp alfa with Keytruda resulted in a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, indicating a significant improvement over historical benchmarks in similar patient groups. Additionally, these promising results suggest the potential for ficerafusp alfa to address unmet needs in the treatment landscape for solid tumors, thereby enhancing Bicara Therapeutics's growth prospects and competitive position in the biopharmaceutical market.
Bears say
Bicara Therapeutics reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates, indicating ongoing financial challenges. The company faces multiple risks including potential negative clinical results for its lead product, ficerafusp alfa, as well as delays in progressing the therapy into critical trials and achieving regulatory approvals, which could hinder future growth. Projections indicate a substantial full-year net loss of $2.27 per share for 2025, slightly improved from earlier estimates, but still reflecting persistent financial difficulties that may negatively impact investor confidence.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares